Standardized MRD quantification in European ALL trials: Proceedings of the Second International Symposium on MRD assessment in Kiel, Germany, 18–20 September 2008

Improved risk classification for risk-specific therapy based on the molecular study of minimal residual disease (MRD) in adult acute lymphoblastic leukemia (ALL)

(2009) R. Bassan et al.   BLOOD

Establishment and validation of a standard protocol for the detection of minimal residual disease in B lineage childhood acute lymphoblastic leukemia by flow cytometry in a multi-center setting;

(2009) J. Irving et al.   HAEMATOLOGICA

Risk of Relapse of Childhood Acute Lymphoblastic Leukemia Is Predicted By Flow Cytometric Measurement of Residual Disease on Day 15 Bone Marrow

(2009) Giuseppe Basso et al.   JOURNAL OF CLINICAL ONCOLOGY

Pediatric-Inspired Therapy in Adults With Philadelphia Chromosome–Negative Acute Lymphoblastic Leukemia: The GRAALL-2003 Study

(2009) Françoise Huguet et al.   JOURNAL OF CLINICAL ONCOLOGY

Quality Control of Flow Cytometry Data Analysis for Evaluation of Minimal Residual Disease in Bone Marrow From Acute Leukemia Patients During Treatment

(2009) Elisabet Björklund et al.   JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY

Prognostic significance of minimal residual disease in infants with acute lymphoblastic leukemia treated within the Interfant-99 protocol

(2009) V H J Van der Velden et al.   LEUKEMIA

Quantification of fusion transcript reveals a subgroup with distinct biological properties and predicts relapse in BCR/ABL-positive ALL: implications for residual disease monitoring

(2009) M Zaliova et al.   LEUKEMIA

CD20 up-regulation in pediatric B-cell precursor acute lymphoblastic leukemia during induction treatment: setting the stage for anti-CD20 directed immunotherapy

(2008) M. N. Dworzak et al.   BLOOD

Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children's Oncology Group study

(2008) M. J. Borowitz et al.   BLOOD

Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet

(2008) M. A. Sanz et al.   BLOOD

B-cell reconstitution after allogeneic SCT impairs minimal residual disease monitoring in children with ALL

(2008) E Fronkova et al.   BONE MARROW TRANSPLANTATION

Generation of flow cytometry data files with a potentially infinite number of dimensions

(2008) Carlos E. Pedreira et al.   CYTOMETRY PART A

A probabilistic approach for the evaluation of minimal residual disease by multiparameter flow cytometry in leukemic B-cell chronic lymphoproliferative disorders

(2008) C.E. Pedreira et al.   CYTOMETRY PART A

Standardization of flow cytometric minimal residual disease evaluation in acute lymphoblastic leukemia: Multicentric assessment is feasible

(2008) Michael Norbert Dworzak et al.   CYTOMETRY PART B-CLINICAL CYTOMETRY

Report of the European Myeloma Network on multiparametric flow cytometry in multiple myeloma and related disorders

(2008) A. C. Rawstron et al.   HAEMATOLOGICA

Prognostic Value of Minimal Residual Disease Quantification Before Allogeneic Stem-Cell Transplantation in Relapsed Childhood Acute Lymphoblastic Leukemia: The ALL-REZ BFM Study Group

(2008) Peter Bader et al.   JOURNAL OF CLINICAL ONCOLOGY

Minimal residual disease (MRD) analysis in the non-MRD-based ALL IC-BFM 2002 protocol for childhood ALL: is it possible to avoid MRD testing?

(2008) E Fronkova et al.   LEUKEMIA